摘要
目的探讨重组人血管内皮抑制素注射液联合化疗治疗老年晚期非小细胞肺癌的临床效果。方法选择患者80例,分为两组,每组各40例,对照组化疗方案:多西他塞75 mg/m2联合吉西他滨1000 mg/m2,观察组在对照组的基础上使用重组人血管内皮抑制素注射液,比较两组患者治疗前后的生活质量KPS评分,并统计两组的近期疗效。结果治疗后观察组的生活质量KPS评分显著高于对照组(P<0.05),观察组的有效率为35.0%,显著高于对照组的10.0%(P<0.05)。结论重组人血管内皮抑制素注射液联合化疗应用于晚期非小细胞肺癌患者,能显著提高患者的生活质量,延长生存时间,值得临床推广。
Objective To explore the effect of recombinant human endostatin injection combination with chemstherapy treatment for elderly patients with advanced non-small cell lung cancer. Methods 80 patients were divided into two groups,each group of 40 cases,the control group were used chemotherapy as：docetaxel 75 mg/m2 and gemcitabine 1000 mg/m2,the observation group were used recombinant human endostatin injection combination with chemotherapy based on the control group,then quality of life with KPS before and after treatment and recent statistical effect in the two groups were compared. Results After treatment,the quality of life in the observation group with KPS score was sig- nificantly higher than control group （P〈0.05）,the efficiency of the observation group was 35.0%,it was significantly higher than 10.0% of control group （P〈0.05）. Conclusion The effect of recombinant human endostatin injection combination with chemotherapy for elderly patients with advanced non-small cell lung cancer can significantly improve the quality of life and prolong survival time,so it is worthy of promotion.
出处
《中国当代医药》
2014年第21期94-96,共3页
China Modern Medicine
